gene

MTNR1A

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about MTNR1A: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

351Connections

1Hypotheses

2Analyses

50Outgoing

50Incoming

Summary

MTNR1A is a gene implicated in neurodegeneration research. Key relationships include: co discussed, interacts with, therapeutic target. Associated with neurodegeneration. Connected to 30 entities in the SciDEX knowledge graph.

View on Wiki →

🧬 Gene Info

Gene Symbol	MTNR1A
Protein Type	Gpcr
Target Class	Gpcr
Function	Small molecule agonists that activate G-protein coupled receptor signaling
Mechanism of Action	Small molecule agonists that activate G-protein coupled receptor signaling
Druggability	Medium (0.57)
Clinical Stage	Approved
Pathways	Circadian rhythm / glymphatic clearance, Early neurodevelopment, LRP1 receptor-mediated transcytosis
UniProt ID	Q8WZ72
GeneCards	MTNR1A
Human Protein Atlas	MTNR1A
Associated Diseases	ALS, ALZHEIMER, AUTISM, Alzheimer's disease
Known Drugs/Compounds	NG-497, linalool
Interactions	LRP1, MTNR1B, NPAS2, PER1, PER2, CNR2
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	Circadian Glymphatic Rescue Therapy (Melatonin-foc
KG Connections	351 knowledge graph edges
Databases	GeneCards NCBI Gene HPA STRING

🧬 3D Structure: MTNR1A — PDB 6ME2 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Wiki Pages (20)

Knowledge base pages for this entity

Pathway Diagram

graph TD
    MTNR1A["MTNR1A"] -->|"associated"| neurodegeneration["neurodegeneration"]
    MTNR1A["MTNR1A"] -->|"interacts"| LRP1["LRP1"]
    MTNR1A["MTNR1A"] -->|"interacts"| MTNR1B["MTNR1B"]
    MTNR1A["MTNR1A"] -->|"co discussed"| CX3CR1["CX3CR1"]
    MTNR1A["MTNR1A"] -->|"co discussed"| HCRT["HCRT"]
    MTNR1A["MTNR1A"] -->|"co discussed"| CACNA1G["CACNA1G"]
    LRP1_1["LRP1"] -->|"interacts"| MTNR1A["MTNR1A"]
    MTNR1B_2["MTNR1B"] -->|"interacts"| MTNR1A["MTNR1A"]
    BMAL1["BMAL1"] -->|"co discussed"| MTNR1A["MTNR1A"]
    HCRTR2["HCRTR2"] -->|"co discussed"| MTNR1A["MTNR1A"]
    style MTNR1A fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (226)

Target	Relation	Type	Str
NMDA receptor	regulates	receptor	0.90
NMDA receptor	associated_with	receptor	0.90
NMDA receptor	expressed_in	receptor	0.90
Insomnia	therapeutic_target	disease	0.90
cAMP/PKA signaling pathway	activates	pathway	0.90
NMDA receptor	interacts_with	receptor	0.80
MTNR1B	co_mentioned_with	gene	0.80
AQP4	regulates_expression	gene	0.80
melatonin_receptor	encodes	protein	0.80
NMDA receptor	protects_against	receptor	0.70
NMDA receptor	treats	receptor	0.70
NMDA receptor	activates	receptor	0.70
DEPRESSION	biomarker_for	disease	0.70
Sleep Disorder	expressed_in	disease	0.65
circadian regulation	participates_in	pathway	0.65
Depression	activates	disease	0.65
Als	expressed_in	disease	0.65
Autism	expressed_in	disease	0.65
Cancer	activates	disease	0.65
Glioblastoma	activates	disease	0.65
Alzheimer	associated_with	disease	0.65
Als	associated_with	disease	0.65
Als	activates	disease	0.65
Neuroinflammation	regulates	disease	0.65
Alzheimer	expressed_in	disease	0.65
Cancer	expressed_in	disease	0.65
Alzheimer	interacts_with	disease	0.65
Als	interacts_with	disease	0.65
Bipolar	regulates	disease	0.65
ALS	expressed_in	disease	0.65
Tumor	activates	disease	0.65
ALS	associated_with	disease	0.65
ALS	activates	disease	0.65
Inflammation	regulates	disease	0.65
Inflammation	activates	disease	0.65
ALS	interacts_with	disease	0.65
Bipolar	methylates	disease	0.65
Alzheimer	inhibits	disease	0.65
Cancer	inhibits	disease	0.65
neurodegeneration	implicated_in	disease	0.60
Circadian rhythm	regulates	pathway	0.60
Membranous nephropathy	therapeutic_target	disease	0.60
Mitochondrial dysfunction	regulates	pathway	0.60
DRP1	regulates	gene	0.60
Circadian rhythm disruption	regulates	pathway	0.60
Early neurodevelopment	involved_in	pathway	0.60
Sleep development	regulates	pathway	0.60
Gonadotropin secretion	regulates	pathway	0.60
PER2	associated_with	gene	0.60
PER3	expressed_in	gene	0.60

Incoming (125)

Source	Relation	Type	Str
h-7e0b5ade	targets_gene	hypothesis	0.90
h-de579caf	targets_gene	hypothesis	0.90
h-7e0b5ade	targets	hypothesis	0.80
h-de579caf	targets	hypothesis	0.80
linalool	targets	compound	0.80
rs12506228	associated_with	gene	0.60
NG-497	modulates	drug	0.60
MTNR1B	activates	gene	0.60
NPAS2	associated_with	gene	0.60
MTNR1B	expressed_in	gene	0.60
APP	activates	gene	0.60
RS12506228	associated_with	gene	0.60
CXCL12	associated_with	gene	0.60
ADCY2	associated_with	gene	0.60
GRM2	associated_with	gene	0.60
NPY	associated_with	gene	0.60
CXCL8	associated_with	gene	0.60
CCR5	associated_with	gene	0.60
MTNR1B	associated_with	gene	0.60
ARNTL	expressed_in	gene	0.60
PER3	expressed_in	gene	0.60
IL6	expressed_in	gene	0.60
NR1D1	expressed_in	gene	0.60
IL6	inhibits	gene	0.60
C3AR1	associated_with	gene	0.60
APP	regulates	gene	0.60
APP	suppresses	gene	0.60
ADCY2	interacts_with	gene	0.60
C3AR1	interacts_with	gene	0.60
CCR5	interacts_with	gene	0.60
CNR2	interacts_with	gene	0.60
CXCL12	interacts_with	gene	0.60
CXCL8	interacts_with	gene	0.60
GRM2	interacts_with	gene	0.60
CNR2	binds_to	gene	0.60
CLOCK	binds_to	gene	0.60
MT1	expressed_in	gene	0.60
GABRA1	associated_with	gene	0.60
FOXO1	activates	gene	0.60
FOXO1	interacts_with	gene	0.60
GABRA1	targets	gene	0.60
GABRB2	targets	gene	0.60
HTR1A	targets	gene	0.60
AQP4	expressed_in	gene	0.60
LRP1	expressed_in	gene	0.60
Melatonin	binds_to	drug	0.60
DEPRESSION	activates	gene	0.60
AMYLOID	activates	gene	0.60
ALZHEIMER	associated_with	gene	0.60
MICROGLIA	regulates	gene	0.60

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Circadian Glymphatic Rescue Therapy (Melatonin-focused)	0.546	neurodegeneration	Sleep disruption as cause and consequenc

Mentioning Analyses (2)

Scientific analyses that reference this entity

Sleep disruption as cause and consequence of neurodegeneration

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.557

Blood-brain barrier transport mechanisms for antibody therapeutics

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.566

Related Papers (17)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress di [PMID:33285346]	Cénat JM, Blais-Rochette C, Kokou-Kpolou	Psychiatry Res	2021	1
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Seque [PMID:32822576]	Maynard A, McCoach CE, Rotow JK, Harris	Cell	2020	1
The Ca(2+) Sensor SCaBP3/CBL7 Modulates Plasma Membrane H(+)-ATPase Activity and [PMID:30962395]	Yang Y, Wu Y, Ma L, Yang Z, Dong Q, Li Q	Plant Cell	2019	1
Sleep drives metabolite clearance from the adult brain. [PMID:24136970]	Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Th	Science	2013	1
Impact of preinterventional plaque composition and eccentricity on late-acquired [PMID:22936019]	Sato T, Kameyama T, Noto T, Nozawa T, In	Coron Artery Dis	2012	1
Melatonin Promotes the Synthesis and Secretion of Growth Hormone in the Adenohyp [PMID:41870323]	["Zheng Y", "Chen Q", "Guo H", "Zhang Y"	Journal of pineal research	2026	0
Screening natural raw materials and product development for improving insomnia b [PMID:41578474]	["Yue L", "Jiao Q", "Li J", "Lu Y", "Yi	Medicine	2026	0
Pharmacological modulation of MRAP2 protein on murine melatonin receptor signali [PMID:40510472]	Song W, Li Y, Xu H, Zhang Y, Liu L, Li Y	Frontiers in endocrinology	2025	0
Regulation of therapeutic protein release in response to circadian biomarkers. [PMID:41198646]	Franko N, Li S, Galvan S, Csorba Z, Teix	Nature communications	2025	0
Polymorphisms in MTNR1A (rs2119882) and CLOCK (rs1801260) genes are associated w [PMID:40705802]	Chi Y, Yang X, Deng D, Li P, Zhang Y	PloS one	2025	0
Finger friction with leather and seam of new and used softballs with and without [PMID:35678234]	["Kinoshita H"]	Sports biomechanics	2024	0
System-Level Strategies to Improve Home Dialysis: Policy Levers and Quality Init [PMID:37678234]	["Watnick S", "Blake P", "Mehrotra R", "	Clinical journal of the Americ	2023	0
Recommendations for risk minimization when using Janus kinase inhibitors for the [PMID:37345890]	["Wohlrab J", "Kegel T", "Gro\u00dfe R",	Journal der Deutschen Dermatol	2023	0
In Vitro Anticancer Activity of the Light Stable Zinc Isotope (64Zn) Compounds. [PMID:36456123]	["Novak P", "Balakin A", "Temnik M"]	Anticancer research	2022	0
A long-term follow-up study on otoacoustic emissions testing in paediatric patie [PMID:31234890]	["Reiterer E", "Reider S", "Lackner P",	Malaria journal	2019	0
Severe refractory idiopathic warm autoimmune haemolytic anaemia responsive to co [PMID:30567234]	["Neave L", "Wilson A", "Lissack M", "Sc	BMJ case reports	2018	0
Metformin and lung cancer risk in patients with type 2 diabetes mellitus. [PMID:28456789]	["Tseng C"]	Oncotarget	2017	0

MTNR1A

Understanding Entity Pages

Summary

Wiki Pages (20)

Blood-Brain Barrier Dysfunction in Neurodegeneration

Melatonin for Tauopathy: Comprehensive Evidence Synthesis

Blood-Brain Barrier Biology and Crossing Strategies

Section 153: Virtual Reality Therapy Protocols in CBS/PSP

Blood-Brain Barrier Breakdown in Neurodegeneration

blood-brain-barrier-endothelial-cells

Blood-Based Biomarkers for Neurodegeneration

Blood Microbial Signatures in Parkinson's Disease

Blood-Brain Barrier

section-181-advanced-music-rhythm-therapy-cbs-psp

Advanced Metal Chelation Therapy in CBS/PSP

PROTAC Therapy for Parkinson's Disease

Virtual Reality Therapy for CBS/PSP Gait Training

section-155-art-therapy-creative-arts-therapies-cbs-psp

Blood-Brain Barrier Penetration Technologies Investment Landscape

RMF Therapy for Parkinson's Disease

Section 137: Advanced Metal Chelation Therapy in CBS/PSP

Speech Therapy for Parkinson's Disease

Focused Ultrasound Thalamotomy

Blood-Brain Barrier in 4R-Tauopathies